share_log

West Pharmaceutical Services' (NYSE:WST) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth

West Pharmaceutical Services' (NYSE:WST) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth

西部制药服务公司(纽约证券交易所代码:WST)五年期股东总回报率超过基础收益增长
Simply Wall St ·  2023/10/25 06:24

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a good company can see its share price rise well over 100%. For instance, the price of West Pharmaceutical Services, Inc. (NYSE:WST) stock is up an impressive 266% over the last five years. On the other hand, the stock price has retraced 4.0% in the last week. But note that the broader market is down 3.7% since last week, and this may have impacted West Pharmaceutical Services' share price.

你在任何一只股票上最多只能损失100%的钱(假设你不使用杠杆)。但在较轻松的情况下,一家好公司的股价涨幅可以远远超过100%。例如,价格,西部医药服务公司。(纽约证券交易所股票代码:WST)的股票在过去五年中上涨了266%,令人印象深刻。另一方面,股价在过去一周回调了4.0%。但请注意,自上周以来,大盘下跌了3.7%,这可能影响了West Pharmtics Services的股价。

Although West Pharmaceutical Services has shed US$1.1b from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

尽管西方医药服务公司本周市值缩水11亿美元,但让我们来看看它的长期基本面趋势,看看它们是否推动了回报。

See our latest analysis for West Pharmaceutical Services

查看我们对西方医药服务公司的最新分析

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

不可否认,市场有时是有效的,但价格并不总是反映潜在的商业表现。考察市场情绪如何随时间变化的一种方法是观察一家公司的股价和每股收益(EPS)之间的相互作用。

Over half a decade, West Pharmaceutical Services managed to grow its earnings per share at 28% a year. So the EPS growth rate is rather close to the annualized share price gain of 30% per year. Therefore one could conclude that sentiment towards the shares hasn't morphed very much. Rather, the share price has approximately tracked EPS growth.

在过去的五年里,西方医药服务公司设法使其每股收益以每年28%的速度增长。因此,每股收益的增长率相当接近股价每年30%的年化涨幅。因此,人们可以得出这样的结论:投资者对这些股票的情绪没有太大变化。相反,该公司股价已大致追随每股收益的增长。

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

下图显示了EPS是如何随着时间的推移进行跟踪的(如果您点击该图像,您可以看到更多详细信息)。

earnings-per-share-growth
NYSE:WST Earnings Per Share Growth October 25th 2023
纽约证券交易所:WST每股收益增长2023年10月25日

This free interactive report on West Pharmaceutical Services' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

免费如果你想进一步调查股票,关于West Pharmtics Services的收益、收入和现金流的互动报告是一个很好的起点。

What About Dividends?

那股息呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, West Pharmaceutical Services' TSR for the last 5 years was 271%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

在考察投资回报时,重要的是要考虑到股东总回报(TSR)和股价回报。虽然股价回报只反映股价的变动,但TSR包括股息的价值(假设股息再投资),以及任何折价集资或分拆所带来的利益。公平地说,TSR为支付股息的股票提供了更完整的图景。碰巧的是,西方医药服务公司最近5年的TSR为271%,超过了前面提到的股价回报。这在很大程度上是其股息支付的结果!

A Different Perspective

不同的视角

It's good to see that West Pharmaceutical Services has rewarded shareholders with a total shareholder return of 57% in the last twelve months. And that does include the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 30% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

很高兴看到,在过去的12个月里,西部药业服务公司以57%的总股东回报回报了股东。这确实包括了股息。由于一年期的TSR好于五年期的TSR(后者的年收益率为30%),看起来该股的表现在最近有所改善。鉴于股价势头依然强劲,仔细观察这只股票可能是值得的,以免错过预期和机会。大多数投资者都会花时间检查内幕交易的数据。你可以点击这里,看看内部人士是在买入还是卖出。

But note: West Pharmaceutical Services may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

但请注意:西方医药服务公司可能不是最值得买入的股票。所以让我们来看看这个免费过去有盈利增长(以及进一步增长预测)的有趣公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发